- $89.76m
- $72.55m
- $19.61m
- 42
- 26
- 94
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.13 | ||
| Price to Tang. Book | 4.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.91% | ||
| Return on Equity | -18.09% | ||
| Operating Margin | -31.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 29.7 | 33.64 | 19.8 | 17.32 | 19.61 | 19.72 | 22.63 | -8.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.
Directors
- Michael Klein CHM (67)
- Stacey Stevens PRE (53)
- Charles Carter CFO (54)
- Jonathan Go CTO (54)
- Nathaniel Dalton LED (54)
- Dana Brown IND (50)
- Timothy Irish IND (58)
- Rakesh Patel IND (48)
- Andrew Sassine IND (56)
- Susan Wood IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 24th, 1984
- Public Since
- December 13th, 1984
- No. of Shareholders
- 91
- No. of Employees
- 66
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 27,365,682
- Address
- 98 Spit Brook Rd Ste 100, NASHUA, 03062-5737
- Web
- https://www.icadmed.com/
- Phone
- +1 6038825200
- Auditors
- BDO USA, LLP
Upcoming Events for ICAD
ICAD Inc Annual Shareholders Meeting
Q2 2025 ICAD Inc Earnings Release
Similar to ICAD
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the icad share price?
As of Today at 21:12 UTC, shares in icad are trading at $3.28. This share price information is delayed by 15 minutes.
How has the icad share price performed this year?
Shares in icad last closed at $3.28 and the price had moved by +121.62% over the past 365 days. In terms of relative price strength the icad share price has outperformed the S&P500 Index by +104.56% over the past year.
What are the analyst and broker recommendations for icad?
The overall consensus recommendation for icad is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the icad dividend yield?
icad does not currently pay a dividend.
Does icad pay a dividend?
icad does not currently pay a dividend.
When does icad next pay dividends?
icad does not currently pay a dividend.
How do I buy icad shares?
To buy shares in icad you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of icad?
As of the previous close price of $3.28, shares in icad had a market capitalisation of $89.76m.
Where are icad shares listed?
Here are the trading details for icad:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ICAD
What kind of share is icad?
Based on an overall assessment of its quality, value and momentum icad is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a icad share price forecast for 2025?
The analyst consensus target price for shares in icad is $3.50. That is 6.71% above the last closing price of $3.28.
Analysts covering icad currently have a consensus Earnings Per Share (EPS) forecast of -$0.22 for the next financial year.
Find out moreWhat is the trend in the icad share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like icad. Over the past six months, its share price has outperformed the S&P500 Index by +76.38%.
As of the last closing price of $3.28, shares in icad were trading +67.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the icad PE Ratio?
The icad PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of icad?
icad's management team is headed by:
- Michael Klein - CHM
- Stacey Stevens - PRE
- Charles Carter - CFO
- Jonathan Go - CTO
- Nathaniel Dalton - LED
- Dana Brown - IND
- Timothy Irish - IND
- Rakesh Patel - IND
- Andrew Sassine - IND
- Susan Wood - IND